A team of technology entrepreneurs behind a previously acquired medical artificial intelligence startup has secured $22 million in funding to launch Aevius, a Boston-based company developing advanced AI systems designed to transform how healthcare organizations analyze and use patient information.
The investment, led by Insight Partners, highlights growing investor interest in artificial intelligence technologies capable of improving medical decision-making, accelerating scientific research and addressing longstanding inefficiencies in the American healthcare system.
Aevius was established by Rowland Pettit, Ming Yang (Max) Lu, Faisal Mahmood and Long Phi Le, entrepreneurs who previously helped create Modella AI.
Modella developed biomedical foundation models and AI agents focused on cancer research before being acquired by pharmaceutical giant AstraZeneca in January 2026.
The acquisition demonstrated the commercial potential of advanced AI in drug development and oncology.
With Aevius, the founders are pursuing a broader opportunity: applying artificial intelligence across multiple diseases, medical specialties and healthcare organizations. Pettit, a physician-scientist, serves as chief executive officer, while Lu leads the company’s technology development.
American healthcare organizations generate enormous quantities of information through electronic medical records, laboratory tests, medical imaging and clinical reports. However, much of this information remains fragmented across different databases and software systems.
These disconnected records make it difficult for physicians and researchers to develop a complete understanding of patients. Aevius aims to address this challenge through AI models that combine structured information, clinical narratives and specialized medical data.
The company’s technology creates continuously updated digital representations of individual patients, incorporating their medical histories and changing health conditions. This approach could help healthcare organizations identify patterns that conventional software systems frequently overlook.
One potential application involves predicting which patients face an elevated risk of hospital readmission. By examining medical histories, laboratory results and other clinical indicators, Aevius aims to help healthcare providers recognize emerging risks before complications develop.
The technology could also identify patients with similar medical characteristics, helping clinicians and researchers compare treatment outcomes. Hospitals may eventually use these insights to improve resource allocation, coordinate care and support more personalized treatment decisions.
However, these applications remain dependent on clinical validation, data quality and responsible implementation. Aevius is targeting three major customer groups: healthcare providers, life sciences companies and health insurers.
For pharmaceutical companies, the platform could support research into disease progression, identify potential biomarkers and improve the selection of participants for clinical trials. Insurers could use the technology to better understand patient populations and identify opportunities for earlier medical intervention.
The company’s broader ambition is to make complex medical information accessible to both healthcare professionals and AI-powered software tools. The $22 million financing will support product development, engineering recruitment, clinical expertise and commercial deployment.
Aevius emerged from Mass General Brigham, one of America’s leading healthcare research institutions. Prominent physician-scientist Eric Topol also chairs the company’s scientific advisory board. Their involvement provides medical and research expertise as the startup develops its technology.
Despite the opportunity, AI-powered healthcare platforms face important obstacles. Patient privacy, cybersecurity, regulatory compliance and algorithmic reliability remain essential concerns.
Medical AI systems must demonstrate that their predictions are accurate, clinically useful and applicable across diverse patient populations. Healthcare providers must also retain appropriate human oversight when using automated recommendations.
Aevius represents a growing movement toward AI systems that understand complete patient histories rather than isolated medical records.
Its founders’ previous success with Modella AI has helped attract institutional investment, while its broader healthcare focus creates opportunities across hospitals, insurers and pharmaceutical research.










